Bicara Therapeutics (BCAX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$55.4M

Net income growth (year over year)

−102.41%

Net margin

—

Return on equity

−41.01%

EPS (trailing twelve months)

−$3.07

Book value per share

$7.11

P/E (trailing twelve months)

—

Price to book

2.47

Debt to assets

8.49%

Payout ratio

—

Dividend yield

—

Company profile

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.

• How do I buy stock in Bicara Therapeutics (BCAX)?

  BCAX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.